Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EPS (Weighted Average and Diluted) (2023 - 2026)

Perspective Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.25 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed 0.0% to -$0.25 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.41, a 13.71% decrease, with the full-year FY2025 number at -$1.41, down 15.57% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.25 in Q1 2026 for Perspective Therapeutics, up from -$0.51 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CATX hit a ceiling of $0.01 in Q1 2023 and a floor of -$1.06 in Q4 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.36 across 4 years, with a median of -$0.3 in 2025.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 47.06% in 2024, down 2600.0% in 2024.
  • Tracing CATX's EPS (Weighted Average and Diluted) over 4 years: stood at -$1.06 in 2023, then skyrocketed by 43.4% to -$0.6 in 2024, then increased by 15.0% to -$0.51 in 2025, then surged by 50.98% to -$0.25 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CATX at -$0.25 in Q1 2026, -$0.51 in Q4 2025, and -$0.35 in Q3 2025.